Patient reported outcomes in a phase 2 trial of SU11248 for metastatic renal cell carcinoma

8167 Background: SU11248 is a novel, oral multi-targeted tyrosine kinase inhibitor with both anti-angiogenic and anti-tumor activity. In a phase 2 study (014) of SU11248 for the treatment of metast...